Cullinan Therapeutics Announces New Preclinical Data for CLN-978 and Global Phase 1b Study in Systemic Lupus Erythematosus
Cullinan will present new preclinical data for CLN-978 and details of a Phase 1b study in lupus at ACR 2024.Quiver AI SummaryCullinan Therapeutics, Inc. announced that it will present new preclinical data...
Cullinan Therapeutics: Q3 Earnings Snapshot
Cullinan Therapeutics: Q3 Earnings Snapshot
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
/PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc., announced today the launch of the REZILIENT3 trial...
Why Shares of Cullinan Oncology Jumped This Week
The company's presentation at a conference got the attention of analysts and investors.
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented updated Phase 1/2a data...